Aug 07, 2017 4:05 pm EDT Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights
Aug 02, 2017 8:00 am EDT Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
Jul 31, 2017 8:10 am EDT Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS)
May 10, 2017 5:00 pm EDT Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2017 8:00 am EDT Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team
May 04, 2017 4:15 pm EDT Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights
Apr 21, 2017 8:00 am EDT Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC)
Apr 20, 2017 4:20 pm EDT Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017
Apr 03, 2017 8:00 am EDT Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer